Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Sundance Resources Limited

ABN

19 055 719 394

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to Fube issued

Fully paid ordinary shares

2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued

3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion) 26,666,667 shares

26,666,667 Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do	Yes
	<ul> <li>not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> </ul>	
	<ul> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	\$0.00375 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Financial Support Undertaking as per the Second Agreement for cancellation of Existing Notes (" <b>New Agreement</b> ") signed on 5 July 2019.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h <i>in relation to the</i> + <i>securities</i> <i>the subject of this Appendix 3B</i> , and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of +securities issued without security holder approval under rule 7.1	Issued under rule 7.1
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	N/A

<sup>+</sup> See chapter 19 for defined terms.

- 6e Number of <sup>+</sup>securities issued N/A with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If +securities issued under rule N/A 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- 6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and \*class of all \*securities quoted on ASX (*including* the \*securities in section 2 if applicable)

N/A

N/A

7.1 - **66,377,043** 7.1A - **837,584,695** 

6 August 2019

 Number
 +Class

 9,025,846,952
 Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9

		Number	+Class
•	Number and +class of all +securities not quoted on ASX ( <i>including</i> the +securities in section 2 if applicable)	260,000,000	Unquoted Investor Consortium Options exercisable at \$0.0695 per share
		200,000,000	Unquoted Noble Options exercisable at \$0.0695 per option
		260,000,000	Unquoted Wafin Options exercisable at \$0.0695 per option
		100,000,000	Unquoted 2017 Options exercisable at \$0.003 per option expiring 7 April 2022
		100,000,000	Unquoted 2017 Options exercisable at \$0.006 per option vesting 1 December 2018 and expiring on 7 April 2023
		110,000,000	Unquoted Options exercisable at \$0.006 per option expiring 8 January 2024
		400,000,000	Unquoted Options exercisable at \$0.006 per option expiring 13 February 2024
		30,000,000	Unquoted Options exercisable at \$0.006 per option expiring 21 February 2024
		Total unquoted options: 1,460,000,000	
		200,000	Noble Convertible Notes
		240,000	Investor Consortium Convertible Notes
		400,000	Wafin Convertible Notes
		70,000	2015 Investor Group Convertible Notes
		2,600	2016 Investor Group Convertible Notes
		Total Convertible Notes: 912,600	

<sup>+</sup> See chapter 19 for defined terms.

# Part 2 - Pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or nonrenounceable?
- 13 Ratio in which the +securities will be offered
- 14 +Class of +securities to which the offer relates
- 15 \*Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated calculating for entitlements?
- Policy for deciding entitlements 17 in relation to fractions
- 18 Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

- 19 Closing date for receipt of acceptances or renunciations
- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue

N/A

23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
20	Line of a construction of the second	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
00		
33	+Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of *securities ( <i>tick one</i> )
(a)	*Securities described in Part 1
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional +securities

#### Entities that have ticked box 34(b)

- 38 Number of \*securities for which \*quotation is sought
- 39 <sup>+</sup>Class of <sup>+</sup>securities for which quotation is sought



<sup>+</sup> See chapter 19 for defined terms.

40 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another <sup>+</sup>security, clearly identify that other <sup>+</sup>security)

42 Number and +class of all +securities quoted on ASX (*including* the +securities in clause 38)

Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- +Quotation of our additional +securities is in ASX's absolute discretion. ASX 1 may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the • +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 6 August 2019

(Company secretary)

CAROL MARINKOVICH

Print name:

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Г

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	8,313,346,952	
Add the following:	Issued under Listing Rule 7.2	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	Nil	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	<ul> <li>Ratified / Approved at AGM 30/1/19</li> <li>16 October 2018 – 62,500,000</li> </ul>	
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<i>Subtract</i> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	-	
" <b>A</b> "	8,375,846,952	

-

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15 [Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	1,256,377,043
Step 3: Calculate "C", the amoun 7.1 that has already been used	t of placement capacity under rule
<ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	<ul> <li>Placement Capacity</li> <li>9 January 2019 - 55,000,000</li> <li>9 January 2019 - 110,000,000 Unlisted options at \$0.006 per option expiring 8 January 2024</li> <li>14 February 2019 - 200,000,000</li> <li>14 February 2019 - 400,000,000 Unlisted options at \$0.006 per option expiring 13 February 2024</li> <li>22 February 2019 - 15,000,000</li> <li>22 February 2019 - 30,000,000 Unlisted options at \$0.006 per option expiring 21 February 2024</li> <li>8 April 2019 - 300,000,000</li> <li>12 July 2019 - 53,333,333</li> <li>6 August 2019 - 26,666,667</li> </ul>
"C" Step 4: Subtract "C" from ["A" x	1,190,000,000
placement capacity under rule 7.	
"A" x 0.15 Note: number must be same as shown in Step 2	1,256,377,043
Subtract "C"	1,190,000,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	66,377,043

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<b>"A"</b> Note: number must be same as shown in	8,375,846,952	
Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	837,584,695	
Step 3: Calculate "E", the amount of placement capacity under rule         7.1A that has already been used         Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	0	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	837,584,695	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" × 0.10] – "E"	837,584,695	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.